Evidence map›Paper›PMID 38965703›Full record

ArticleDatabase : the journal of biological databases and curation2024

SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population.

José M Moreno-Cabrera, Lidia Feliubadaló, Marta Pineda, Patricia Prada-Dacasa, Mireia Ramos-Muntada, Jesús Del Valle, Joan Brunet, Bernat Gel, María Currás-Freixes, Bruna Calsina and 35 more

Abstract read
In one paragraph

Article in Database : the journal of biological databases and curation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

José M Moreno-CabreraHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.ORCID 0000-0001-8570-0345
Lidia FeliubadalóHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.ORCID 0000-0002-1736-0112
Marta PinedaHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Patricia Prada-DacasaHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Mireia Ramos-MuntadaHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Jesús Del ValleHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.ORCID 0000-0003-3607-7045
Joan BrunetHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.ORCID 0000-0003-1945-3512
Bernat GelHereditary Cancer Group, Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Ctra de Can Ruti, Camí de les Escoles, s/n, Badalona 08916, Spain.ORCID 0000-0001-8878-349X
María Currás-FreixesFamilial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain.
Bruna CalsinaFamilial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain.ORCID 0000-0002-6922-9415
Milton E Salazar-HidalgoFamilial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro, 3, Madrid 28029, Spain.
Marta Rodríguez-BaladaInstitut d'Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus (HUSJR), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Dr. Josep Laporte, 2, Reus 43204, Spain.
Bàrbara RoigInstitut d'Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus (HUSJR), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Dr. Josep Laporte, 2, Reus 43204, Spain.
Sara Fernández-CastillejoInstitut d'Oncologia de la Catalunya Sud (IOCS), Hospital Universitari Sant Joan de Reus (HUSJR), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), Dr. Josep Laporte, 2, Reus 43204, Spain.
Mercedes Durán DomínguezCancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid-Spanish National Research Council (IBGM, UVa- CSIC), Sanz y Fores, 3, Valladolid 47003, Spain.
Mónica Arranz LedoCancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid-Spanish National Research Council (IBGM, UVa- CSIC), Sanz y Fores, 3, Valladolid 47003, Spain.
Mar Infante SanzCancer Genetics Group, Unit of Excellence Institute of Biomedicine and Molecular Genetics, University of Valladolid-Spanish National Research Council (IBGM, UVa- CSIC), Sanz y Fores, 3, Valladolid 47003, Spain.
Adela CastillejoUnidad de Genética Molecular, Hospital General Universitario de Elche. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Av. de Catalunya, 21, Elche 03203, Spain.
Estela DámasoUnidad de Genética Molecular, Hospital General Universitario de Elche. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Av. de Catalunya, 21, Elche 03203, Spain.ORCID 0000-0002-9650-7791
José L SotoUnidad de Genética Molecular, Hospital General Universitario de Elche. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Av. de Catalunya, 21, Elche 03203, Spain.
Montserrat de MiguelLaboratorio de cáncer hereditario, Servicio de Bioquímica clínica-Análisis clínicos, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Madrid 28041, Spain.
Beatriz Hidalgo CaleroLaboratorio de cáncer hereditario, Servicio de Bioquímica clínica-Análisis clínicos, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Madrid 28041, Spain.
José M Sánchez-ZapardielLaboratorio de cáncer hereditario, Servicio de Bioquímica clínica-Análisis clínicos, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, Madrid 28041, Spain.
Teresa Ramon Y CajalFamilial Cancer Clinic, Medical Oncology, Hospital de la Santa Creu i Sant Pau, Sant Quintí, 89, Barcelona 08041, Spain.
Adriana LasaGenetics Department, Hospital de la Santa Creu i Sant Pau, Sant Quintí, 89, Barcelona 08041, Spain.
Alexandra Gisbert-BeamudInstitut de Recerca Sant Pau (IR Sant Pau), Sant Quintí, 77, Barcelona 08041, Spain.
Anael López-NovoFundación Pública Galega de Medicina Xenómica (SERGAS), Instituto de Investigación Sanitaria de Santiago, Grupo de Medicina Xenómica-USC, Av. Barcelona, s/n, Santiago de Compostela 15706, Spain.
Clara Ruiz-PonteBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
Miriam PotronyBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
María I Álvarez-MoraBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
Ana OsorioBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
Isabel Lorda-SánchezBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
Mercedes RobledoBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.ORCID 0000-0001-6256-5902
Alberto CascónBiomedical Network Research Centre On Rare Diseases (CIBERER), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid 28029, Spain.
Anna RuizGenetics Laboratory, Center for Genomic Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Plaça Torre de l'Aigua, s/n, Sabadell 08208, Spain.
Nino SpataroGenetics Laboratory, Center for Genomic Medicine, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Plaça Torre de l'Aigua, s/n, Sabadell 08208, Spain.
Imma HernanMolecular Genetics Unit, Consorci Sanitari de Terrassa, Ctra. Torrebonica, S/N, Terrassa 08227, Spain.
Emma BorràsMolecular Genetics Unit, Consorci Sanitari de Terrassa, Ctra. Torrebonica, S/N, Terrassa 08227, Spain.
Alejandro Moles-FernándezDepartment of Clinical and Molecular Genetics, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Hospital Universitari, Pg. de la Vall d'Hebron, 119, Barcelona 08035, Spain.
Julie EarlCentro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
Juan CadiñanosFundación Centro Médico de Asturias, José María Richard Grandío, s/n, Oviedo, Asturias 33193, Spain.
Ana B Sánchez-HerasCancer Genetic Counseling Unit, Medical Oncology Department, Elche General University Hospital, Almazara, 11, Elche 03203, Spain.
Anna BigasCentro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III, Monforte de Lemos, 3-5, Madrid, 28029, Spain.
Gabriel CapelláHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.
Conxi LázaroHereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL-ONCOBELL, L'Hospitalet de Llobregat, Barcelona 08908, Spain.

Funding

CIBER - Consorcio Centro de Investigación Biomédica en Red (CIBERONC) CB16/12/00234Department of Research and Universities of the Generalitat de Catalunya and AGAUR 2023SGR01112Instituto de Salud Carlos III and Ministerio de Ciencia e Innovación, funded by FEDER funds - a way to build Europe - PI19/00553 PI23/00017
6 · The paper itself

Abstract

Accurate classification of genetic variants is crucial for clinical decision-making in hereditary cancer. In Spain, genetic diagnostic laboratories have traditionally approached this task independently due to the lack of a dedicated resource. Here we present SpadaHC, a web-based database for sharing variants in hereditary cancer genes in the Spanish population. SpadaHC is implemented using a three-tier architecture consisting of a relational database, a web tool and a bioinformatics pipeline. Contributing laboratories can share variant classifications and variants from individuals in Variant Calling Format (VCF) format. The platform supports open and restricted access, flexible dataset submissions, automatic pseudo-anonymization, VCF quality control, variant normalization and liftover between genome builds. Users can flexibly explore and search data, receive automatic discrepancy notifications and access SpadaHC population frequencies based on many criteria. In February 2024, SpadaHC included 18 laboratory members, storing 1.17 million variants from 4306 patients and 16 343 laboratory classifications. In the first analysis of the shared data, we identified 84 genetic variants with clinically relevant discrepancies in their classifications and addressed them through a three-phase resolution strategy. This work highlights the importance of data sharing to promote consistency in variant classifications among laboratories, so patients and family members can benefit from more accurate clinical management. Database URL: https://spadahc.ciberisciii.es/.

Indexed as

Databases, GeneticGenes, NeoplasmGenetic Predisposition to DiseaseGenetic VariationHumansNeoplasmsSpain

Identifiers

PMID38965703
PMCPMC11223915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.